Pacira BioSciences, Inc. (PCRX) Form 10-Q — Aug 4, 2026
Pacira BioSciences reported Q2 2026 total revenues of $192.4 million, up about 6% from $181.1 million a year earlier, and swung to net income of $4.7 million ($0.12 per diluted share) from a $4.8 million loss in Q2 2025. EXPAREL sales rose to $147.8 million and ZILRETTA to $32.6 million, while first-half operating cash flow improved to $83.1 million from $47.5 million. The company completed the divestiture of its iovera° cryoanalgesia business to Zimmer, a Zimmer Biomet subsidiary, on July 31, 2026, receiving $73.6 million in cash after adjustments under a deal worth up to $140 million including $70 million of revenue-based milestones through 2031.
Key figures
- Eps
- 0.12
- Revenue
- 192399000
- Net Income
- 4653000
- Total Debt
- 363124000
- Revenue Yoy
- +6.2% vs Q2 2025 revenue of $181.1 million
- Total Assets
- 1243978000
- Cash Position
- 205875000
- Shares Outstanding
- 39861886
- Six month eps
- 0.19
- Iovera q2 sales
- 6806000
- Q2 2025 revenue
- 181099000
- Exparel q2 sales
- 147823000
- Six month revenue
- 369775000
- Zilretta q2 sales
- 32648000
- Buyback h1 2026 usd
- 50400000
- Revolver all in rate
- 6.72%
- Revolver outstanding
- 81000000
- Six month net income
- 7569000
- Buyback h1 2026 shares
- 2244553
- Iovera upfront payment
- 70000000
- Short term investments
- 45156000
- Convertible notes coupon
- 2.125%
- Stock price june 30 2026
- 25.37
- Conversion price per share
- 39.56
- Convertible notes maturity
- May 15, 2029
- Convertible notes principal
- 287500000
- Iovera deal total potential
- 140000000
- Operating cash flow h1 2026
- 83140000
- Iovera contingent milestones
- 70000000
- Iovera cash received at close
- 73600000
- Buyback remaining authorization
- 100000000
- Uk valuation allowance tax benefit
- 6400000
- Top three wholesaler revenue concentration
- 76%
Price after filing
Close on the filing date to close N calendar days later (from $26.97). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.